Receptor, Nerve Growth Factor, antagonists & inhibitors
- Name
- Receptor, Nerve Growth Factor, antagonists & inhibitors
- Accession Number
- DBCAT001753
- Description
Not Available
- Drugs
Drug Drug Description RI 624 Investigated for use/treatment in pain (acute or chronic). Tanezumab Tanezumab has been investigated for the treatment of Osteoarthritis, Knee and Neuralgia, Postherpetic. - Drugs & Drug Targets
Drug Target Type RI 624 Beta-nerve growth factor target